The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Receives Upadacitinib Application for Ankylosing Spondylitis & Approves Tramadol Hydrochloride Oral Solution

FDA Receives Upadacitinib Application for Ankylosing Spondylitis & Approves Tramadol Hydrochloride Oral Solution

September 30, 2020 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The U.S. Food & Drug Administration (FDA) has received a new drug application for upadacitinib to treat ankylosing spondylitis. The agency has also recently approved tramadol hydrochloride as an oral solution for pain management.

You Might Also Like
  • FDA Approves Celecoxib in an Oral Solution
  • FDA Approves Upadacitinib for RA
  • Upadacitinib at the FDA
Also By This Author
  • Medication Preferences & Current Practices for PsA

Upadacitinib Goes to FDA for Ankylosing Spondylitis
In late August, AbbVie Inc., the manufacturer of upadacitinib (Rinvoq), submitted a new drug application to the FDA for upadacitinib to treat ankylosing spondylitis. The treatment, a once-daily, 15 mg dose, is a selective and reversible JAK inhibitor currently approved in the U.S. to treat moderate to severe rheumatoid arthritis.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The application for this new indication is based on results from the phase 2/3 SELECT-AXIS 1 clinical trial. The study’s primary end-point was the achievement of an Assessment of SpondyloArthritis International Society (ASAS) 40 response—an improvement of at least 40% and an absolute improvement from baseline of at least 20 units on a 0–100 scale in at least three of the following domains: patient global assessment of disease activity, pain assessment, physical function (Bath Ankylosing Spondylitis Functional Index) or inflammation; with no worsening in the remaining domain. At week 14 of the study, 52% of upadacitinib-treated patients achieved an ASAS40 response, compared with 26% of placebo-treated patients (P<0.001).

The safety profile of upadacitinib in SELECT-AXIS 1 was consistent with other upadacitinib clinical trials. No new significant safety signals were identified.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Tramadol Hydrochloride as an Oral Solution
On Sept. 8, the FDA approved an oral solution of tramadol hydrochloride (Qdolo) from Athena Biosciences to treat pain in adults who require an opioid analgesic and for whom alternative pain treatments are inadequate. The oral solution is a central opioid agonist that binds to mu opioid receptors and also weakly inhibits norepinephrine/serotonin uptake. It will be available as a 5 mg/1 mL dose, giving prescribers flexibility to titrate doses to meet patients’ needs. Additionally, the agent will be useful for patients with dysphagia and others who experience difficulty swallowing.2

This treatment has the same warnings and precautions as tramadol tablets, which are only available in 50 mg doses. Like the branded and other generic tramadol hydrochloride products, this treatment will be a Schedule IV controlled substance (C-IV) when it becomes available, meaning it has a low potential for abuse and a low risk of dependence


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. AbbVie Inc. News release: AbbVie submits regulatory application to FDA for Rinvoq (upadacitinib) for the treatment of adults with active ankylosing apondylitis. 2020 Aug 25.
  2. Athena Bioscience LLC. News release: U.S. FDA approves Athena Bioscience’s new drug application for Qdolo (tramadol hydrochloride) oral solution. PR Newswire. 2020 Sep 8.

Pages: 1 2 | Multi-Page

Filed Under: Drug Updates, Spondyloarthritis Tagged With: Ankylosing Spondylitis, AS Resource Center, FDA, Pain, Pain Management, tramadol hydrochloride, U.S. Food and Drug Administration (FDA), upadacitinib

You Might Also Like:
  • FDA Approves Celecoxib in an Oral Solution
  • FDA Approves Upadacitinib for RA
  • Upadacitinib at the FDA
  • FDA Approves Ixekizumab for Treating Active Ankylosing Spondylitis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)